Cargando…
Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation
Nimbolide, a terpenoid natural product derived from the Neem tree, impairs cancer pathogenicity; however, the direct targets and mechanisms by which nimbolide exerts its effects are poorly understood. Here, we used activity-based protein profiling (ABPP) chemoproteomic platforms to discover that nim...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592714/ https://www.ncbi.nlm.nih.gov/pubmed/31209351 http://dx.doi.org/10.1038/s41589-019-0304-8 |
_version_ | 1783429927480066048 |
---|---|
author | Spradlin, Jessica N. Hu, Xirui Ward, Carl C. Brittain, Scott M. Jones, Michael D. Ou, Lisha To, Milton Proudfoot, Andrew Ornelas, Elizabeth Woldegiorgis, Mikias Olzmann, James A. Bussiere, Dirksen E. Thomas, Jason R. Tallarico, John A. McKenna, Jeffrey M. Schirle, Markus Maimone, Thomas J. Nomura, Daniel K. |
author_facet | Spradlin, Jessica N. Hu, Xirui Ward, Carl C. Brittain, Scott M. Jones, Michael D. Ou, Lisha To, Milton Proudfoot, Andrew Ornelas, Elizabeth Woldegiorgis, Mikias Olzmann, James A. Bussiere, Dirksen E. Thomas, Jason R. Tallarico, John A. McKenna, Jeffrey M. Schirle, Markus Maimone, Thomas J. Nomura, Daniel K. |
author_sort | Spradlin, Jessica N. |
collection | PubMed |
description | Nimbolide, a terpenoid natural product derived from the Neem tree, impairs cancer pathogenicity; however, the direct targets and mechanisms by which nimbolide exerts its effects are poorly understood. Here, we used activity-based protein profiling (ABPP) chemoproteomic platforms to discover that nimbolide reacts with a novel functional cysteine crucial for substrate recognition in the E3 ubiquitin ligase RNF114. Nimbolide impairs breast cancer cell proliferation in-part by disrupting RNF114 substrate recognition, leading to inhibition of ubiquitination and degradation of the tumor-suppressors such as p21, resulting in their rapid stabilization. We further demonstrate that nimbolide can be harnessed to recruit RNF114 as an E3 ligase in targeted protein degradation applications and show that synthetically simpler scaffolds are also capable of accessing this unique reactive site. Our study highlights the utility of ABPP platforms in uncovering unique druggable modalities accessed by natural products for cancer therapy and targeted protein degradation applications. |
format | Online Article Text |
id | pubmed-6592714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-65927142019-12-17 Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation Spradlin, Jessica N. Hu, Xirui Ward, Carl C. Brittain, Scott M. Jones, Michael D. Ou, Lisha To, Milton Proudfoot, Andrew Ornelas, Elizabeth Woldegiorgis, Mikias Olzmann, James A. Bussiere, Dirksen E. Thomas, Jason R. Tallarico, John A. McKenna, Jeffrey M. Schirle, Markus Maimone, Thomas J. Nomura, Daniel K. Nat Chem Biol Article Nimbolide, a terpenoid natural product derived from the Neem tree, impairs cancer pathogenicity; however, the direct targets and mechanisms by which nimbolide exerts its effects are poorly understood. Here, we used activity-based protein profiling (ABPP) chemoproteomic platforms to discover that nimbolide reacts with a novel functional cysteine crucial for substrate recognition in the E3 ubiquitin ligase RNF114. Nimbolide impairs breast cancer cell proliferation in-part by disrupting RNF114 substrate recognition, leading to inhibition of ubiquitination and degradation of the tumor-suppressors such as p21, resulting in their rapid stabilization. We further demonstrate that nimbolide can be harnessed to recruit RNF114 as an E3 ligase in targeted protein degradation applications and show that synthetically simpler scaffolds are also capable of accessing this unique reactive site. Our study highlights the utility of ABPP platforms in uncovering unique druggable modalities accessed by natural products for cancer therapy and targeted protein degradation applications. 2019-06-17 2019-07 /pmc/articles/PMC6592714/ /pubmed/31209351 http://dx.doi.org/10.1038/s41589-019-0304-8 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Spradlin, Jessica N. Hu, Xirui Ward, Carl C. Brittain, Scott M. Jones, Michael D. Ou, Lisha To, Milton Proudfoot, Andrew Ornelas, Elizabeth Woldegiorgis, Mikias Olzmann, James A. Bussiere, Dirksen E. Thomas, Jason R. Tallarico, John A. McKenna, Jeffrey M. Schirle, Markus Maimone, Thomas J. Nomura, Daniel K. Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
title | Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
title_full | Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
title_fullStr | Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
title_full_unstemmed | Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
title_short | Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
title_sort | harnessing the anti-cancer natural product nimbolide for targeted protein degradation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592714/ https://www.ncbi.nlm.nih.gov/pubmed/31209351 http://dx.doi.org/10.1038/s41589-019-0304-8 |
work_keys_str_mv | AT spradlinjessican harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT huxirui harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT wardcarlc harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT brittainscottm harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT jonesmichaeld harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT oulisha harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT tomilton harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT proudfootandrew harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT ornelaselizabeth harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT woldegiorgismikias harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT olzmannjamesa harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT bussieredirksene harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT thomasjasonr harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT tallaricojohna harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT mckennajeffreym harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT schirlemarkus harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT maimonethomasj harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation AT nomuradanielk harnessingtheanticancernaturalproductnimbolidefortargetedproteindegradation |